OK-INBRE REQUEST FOR APPLICATIONS FOR RESEARCH PROJECTS
The Oklahoma IDeA Network of Biomedical Research Excellence (OK-INBRE) is requesting applications for research projects from full-time, tenure track faculty (or equivalent) at the University of Oklahoma Health Sciences Center (OUHSC) or the Oklahoma Medical Research Foundation (OMRF). OK-INBRE will fund four Research Project Investigator (RPI) Awards with a start date of November 1, 2021 and an end date of April 30, 2024. Funding for awards is anticipated to be $100,000 in direct costs per year. Applications must align with one of the OK-INBRE research themes of 1) Cancer, 2) Developmental Biology, or 3) Infectious Diseases. The application deadline is 5pm on August 13, 2021. Please see the attached funding opportunity announcement for details. Information can also be found on the OK-INBRE website at Funding Opportunities for OUHSC and OMRF. Questions regarding this OK-INBRE opportunity can be sent to Dawn Hammon (firstname.lastname@example.org) or Darrin Akins (email@example.com).
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email firstname.lastname@example.org or email@example.com).
- Reckitt is seeking to engage with academic partners to 1) develop approaches to enhance oral drug delivery into the pharyngeal, esophageal, or colon; 2) enhance the safety of OTC medications, or 3) develop natural/non-medicated solutions for upper and lower GI conditions, sore throat, cough, cold, flu, and pain. Submission entails a 1-pg non-confidential summary of technology (deadline 5/27/2021)
- Pfizer’s Centers for Therapeutic Innovation (https://www.pfizercti.com) is seeking collaborative proposals for developing novel therapeutic targets with application in 1) oncology: tumor targeted, immuno-oncology, cancer vaccines; 2) internal medicine: obesity/cachexia, heart failure, diabetic/CKD, NASH/T2D; 3) inflammation and immunology: rheumatology, gastroenterology, medical derm; or 4) rare disease: cardiology, neuro-musc., metabolic, hematology. Preference is for novel biological targets supported by in vivo and in vitro models, enabling genetics and mechanistic insights, translational biochemical or cellular assay and biomarkers. Out of scope: drug repurposing, standalone biomarker assays/platforms, medical devices, cell-based therapies. Proposal template available upon request (submission deadline 6/18/21).
Reopening of Research at OUHSC
The Phase Two Return to Research Plan has allowed for the successful, gradual, and phased reopening of bench laboratory research. One key component of Phase Two was the population density limit of one researcher for every 250 sq ft of laboratory space. This conservative population density was established to minimize COVID-19 risk in the research environment while the Vice President for Research (VPR) office evaluated the effectiveness of the reopening plan. Based upon that review and the current COVID-19 guidance and data, the VPR office, in consultation with the Specific Pathogens Preparedness Operations/Emergency Operations Exec team, has determined that effective Tuesday, June 1, bench laboratory research areas may increase capacity to the extent that allows a 3-foot social between all personnel. In accordance with campus COVID-19 policies, masks must be worn at all times in indoor facilities, including labs. If you are uncertain whether your lab can accommodate your personnel numbers observing the required 3-foot social distancing requirement, please contact Chris Tucker in Operations to request your space be measured for this new COVID capacity. Also in accordance with campus policy, labs remain closed to K-12 students but open to undergraduates, graduates, and post-docs from any institution, provided the following are observed:
- non-HSC individuals will complete the online visitor screening tool prior to their first day on campus
- all individuals will complete the HSC online COVID-19 training module in OnPoint, using their HSC credentials
- all individuals will be required to show proof of a negative COVID test (within past 48 hours) or documentation of COVID vaccination, if required based on screening results
- all individuals will strongly encouraged to be vaccinated against COVID-19
- all individuals will be informed that they must comply with the HSC COVID-19 Response Plan
With these changes, we are retiring the Return to Research Plan and will refer to the OUHSC COVID Response Plan for COVID protocols. If you identify any gaps that this leaves, please email firstname.lastname@example.org. It is expected that all personnel will adhere to the requirements in the OUHSC COVID-19 Response Plan.
UPDATE: HSC COVID-19 Response Plan - effective April 13, 2021
This revised Plan (https://www.ouhsc.edu/coronavirus) includes some minor clarifications to current HSC COVID-19 protocols, as well as some more substantive revisions, including:
Section I Telecommuting – Telecommuting in response to COVID-19 is being phased out.
- By June 2, 2021, at least 50% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By July 1, 2021, at least 75% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By August 1, 2021, 100% of the program’s/area’s workforce will have resumed their regular (pre- COVID) schedule on campus
Section III Social Distancing and Gatherings – Effective June 1, social distance measurement will be 3 feet, except in patient care and eating areas which remain at 6 feet.
-This information is included in the Response Plan now for planning purposes. Our medical and public health experts are hopeful that more students and employees will be able to complete their vaccine series in the next few weeks.
-The 6-foot requirement remains in effect until June 1. Operations will replace signs at that time.
Section V Cleaning Facilities and Equipment – Updated to reflect changes to cleaning protocols in response to recent CDC guidance on cleaning as well as to scientific data regarding COVID-19 surface transmissions.
There are also changes to reflect current clinic screening processes (Section VIII) and international travel (Sections VII and IX), as well as a number of non-substantive changes made for clarification.
Please ensure your area’s Return to Service Plans are updated to reflect these changes.
REMINDER ON COVID-19 MITIGATION STRATEGIES IN THE RESEARCH ENVIRONMENT
With the current increase in COVID-19 cases across Oklahoma, this is a good time to do the following:
- Encourage everyone on your team to telecommute as much as possible; reducing the number of individuals in buildings and the research environment will help in reducing potential transmission of the virus.
- Follow your approved COVID-19 Standard Operating Procedures for your laboratory; be certain these are current and are posted on the lab door and inside the laboratory.
- Familiarize yourself with OU Health Sciences Center COVID-19 Resources
- Follow all masking and social distancing guidelines as described in the OUHSC COVID-19 Return Plan
- (https://www.ouhsc.edu/coronavirus); wash your hands often.
- It’s a good practice to follow the HSC’s COVID-19 protocols even when you are home or in the community – masking, social distancing, and good hand hygiene help protect you, your colleagues, and your loved ones.
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( email@example.com ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
NIAID Funded Extensions for Career Award Recipients Whose Career Trajectories Have Been Significantly Impacted by COVID-19 (NOT-AI-21-051)
NIAID Funded Extensions for Fellowship Award Recipients Whose Career Trajectories Have Been Significantly Impacted by COVID-19 (NOT-AI-21-052)
Notice of Pre-Application Webinar for RFA-CA-21-031, Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO; U01 Clinical Trial Required) and RFA-CA-21-032, (ENICTO Coordinating Center; U24 Clinical Trial Not Allowed) (NOT-CA-21-078)
Notice of Information: Establishment of a Standard THC Unit to be used in Research (NOT-DA-21-049)
Notice of NIDA's participation in NOT-NS-21-049, "Notice of Special Interest (NOSI): NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities" (NOT-DA-21-053)
Notice of NIBIB Participation in PAR-21-166 "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)" (NOT-EB-21-011)
Notice of NIBIB Participation to PA-20-194 "NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)" (NOT-EB-21-015)
Notice of NIBIB Participation to PA-20-195 "NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)" (NOT-EB-21-016)
Notice of Correction to Eligibility Information of RFA-MH-21-180, "BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)" (NOT-MH-21-280)
Notice of Early Termination of PAR-21-159, Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at Institutions Serving Underrepresented Populations or Located in Institutional Development Award (IDeA)-eligible States (C06 Clinical Trial Not Allowed) (NOT-OD-21-112)
Notice of Technical Assistance Webinar for NOT-OD-21-087, Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being NOSI (NOT-OD-21-120)
Request for Information (RFI): Drinking Water Contaminants of Emerging Concern for National Emerging Contaminant Research Initiative (NOT-ES-21-006)
Request for Information (RFI) on Flexibilities to Reduce Administrative Burden While Continuing to Apply the PHS Policy to Zebrafish Immediately After Hatching (NOT-OD-21-118)
Notice to Include AIDS Receipt Dates in PAR-21-109 "Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)" (NOT-AG-21-024)
Notice of Change in Key Dates for RFA-AI-20-077, Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed) (NOT-AI-21-048)
Notice of Correction of Key Dates for PAR-20-284, Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed) (NOT-CA-21-077)
Notice of Change to the Eligibility Information for RFA-DA-22-001, "Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)" (NOT-DA-21-051)
Notice of Change to NOT-EB-21-005 "NIBIB Guidance for Support of Clinical Trial Applications" (NOT-EB-21-017)
Notice of Requirement for Submission of Current and Pending Support Information for the PD(s)/PI(s) of PAR-20-175 Institutional Development Award (IDeA) Networks for Clinical and Translational Research (IDeA-CTR) (U54 Clinical Trial Optional)" (NOT-GM-21-049)
Notice of NICHD Participation in RFA-AI-20-078 "Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)" (NOT-HD-21-030)
Notice of Clarification of Eligibility of Applicant Organizations for RFA-HD-22-013: Population Dynamics Centers Research Infrastructure Program FY 2022 (P2C Clinical Trial Not Allowed) (NOT-HD-21-033)
Notice of Change to Additional Information for NOT-OD-21-094 "Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations to Improve the AI/ML-Readiness of NIH-Supported Data" (NOT-OD-21-119)
Notice of Intent to Publish a Funding Opportunity Announcement for Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 - Clinical Trial Not Allowed) (NOT-CA-21-075)
Notice of Intent to Publish: Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium Coordinating and Data Management Center (PSRC CDMC) (U24 - Clinical Trial Not Allowed) (NOT-CA-21-076)
Notice of Special Interest: Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes (NOT-AA-21-028)
Notice of Special Interest (NOSI): Biology of Lung and Head and Neck Preneoplasia (NOT-CA-21-057)
Notice of Special Interest (NOSI): Early-life Factors and Cancer Development Later in Life (NOT-CA-21-074)
Notice of Special Interest (NOSI): Administrative Supplements to Support Addiction Science and Related Neuroscience
Pilot Research Projects at NIMHD-Funded Research Centers in Minority Institutions (RCMI) (NOT-MD-21-022)
Notice of Special Interest (NOSI): NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities (NOT-NS-21-049)
Please Note: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) (PAR-21-223) – Deadline June 6, 2021 and October 5, 2021
NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) (PAR-21-224)
Deadline September 5, 2021 and January 5, 2022
NIMH Research Education Mentoring Program for HIV/AIDS Researchers (R25 Clinical Trial Not Allowed)
(PAR-21-228) - Deadline September 7, 2021 and September 7, 2022
Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed) (PAR-21-229) - Deadline June 5, 2021 and February 5, 2022
NINDS Exploratory Clinical Trials (U01 - Clinical Trial Required) (PAR-21-236) – Deadline June 5, 2021 and October 5, 2021
Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at Institutions Serving Underrepresented Populations or Located in Institutional Development Award (IDeA)-eligible States (C06 Clinical Trial Not Allowed) (PAR-21-238) – Deadline January 6, 2022
Consortium for Innovative HIV/AIDS Vaccine and Cure Research (UM1 Clinical Trial Not Allowed)
(RFA-AI-21-039) - Deadline August 4, 2021
Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U01 Clinical Trial Required) (RFA-CA-21-031) – Deadline July 14, 2021
Coordinating Center for Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U24 Clinical Trial Not Allowed) (RFA-CA-21-032) - Deadline July 14, 2021
Standardization of C-Peptide and HbA1C Measurements Program (U01 Clinical Trial Not Allowed)
(RFA-DK-21-007) - Deadline October 20, 2021
Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed) (RFA-DK-21-011) - Deadline March 9, 2022 and October 7, 2022
Integrated Pathogen Reduction Technologies for Whole Blood and Blood Components for Transfusion (R01) Clinical Trials Not Allowed (RFA-FD-21-032) – Deadline July 6, 2021
Human Milk as a Biological System (R01 Clinical Trial Optional) (RFA-HD-22-020) - Deadline November 29, 2021
NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) (RFA-HL-23-004) – Deadline February 15, 2022
NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) (RFA-HL-23-005) – Deadline February 15, 2022
Research Program Award (R35 Clinical Trial Optional) (RFA-NS-21-020) - Deadline July 13, 2021
BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional) (RFA-NS-21-023) – Deadline July 1, 2021 and October 20, 2021
BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional) (RFA-NS-21-024) - Deadline July 1, 2021 and October 20, 2021
OTHER FEDERAL DEADLINES
Department of Defense (DOD) – Melanoma Research Program (MRP) – Idea Award – Required PreApplication due June 29, 2021
DOD – MRP – Melanoma Academy Leadership Award – Required Preapplication due August 4, 2021
DOD – MRP – Melanoma Academy Scholar Award – Required Preapplication due June 29, 2021
DOD – MRP – Mid-Career Accelerator Award – Required Preapplication due August 4, 2021
DOD – MRP – Team Science Award – Required Preapplication due August 4, 2021
DOD – MRP – Translational Research Award – Required Preapplication due August 4, 2021
Cystic Fibrosis Foundation (CFF) – Women’s Health Research Working Group – Deadline May 28, 2021
CFF – NACFC Case Summary Submissions for Pediatric and Adult Fellows – Deadline June 11, 2021
Chan Zuckerberg Initiative – Ancestry Networks for the Human Cell Atlas – Deadline May 25, 2021